105,500 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by DAFNA Capital Management LLC

DAFNA Capital Management LLC acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 105,500 shares of the company's stock, valued at approximately $1,838,000. DAFNA Capital Management LLC owned 0.19% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BCAX. Geode Capital Management LLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth approximately $1,239,000. JPMorgan Chase & Co. increased its holdings in Bicara Therapeutics by 8,768.5% in the fourth quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock valued at $1,128,000 after buying an additional 64,010 shares during the last quarter. Legal & General Group Plc acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $33,000. Bank of New York Mellon Corp acquired a new stake in Bicara Therapeutics in the fourth quarter valued at $701,000. Finally, Rhumbline Advisers purchased a new stake in Bicara Therapeutics during the fourth quarter worth approximately $331,000.

Bicara Therapeutics Stock Down 1.8 %

Shares of NASDAQ:BCAX traded down $0.23 during midday trading on Friday, hitting $12.90. The stock had a trading volume of 729,786 shares, compared to its average volume of 487,077. Bicara Therapeutics Inc. has a 1 year low of $8.91 and a 1 year high of $28.09. The stock has a 50 day moving average price of $12.95 and a two-hundred day moving average price of $15.57.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). As a group, equities research analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. HC Wainwright cut their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wells Fargo & Company began coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price on the stock. Finally, Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $32.43.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.